FDA has granted Fast Track, Rare Pediatric Disease, and Orphan Drug Designation for EPI-321 in FSHD SOUTH SAN FRANCISCO, CA, USA I August 05, 2025 I Epicrispr Biotechnologies, a clinical-stage company ...

AMSTERDAM, The Netherlands; ZUG, Switzerland & GDAŃSK, Poland I August 05, 2025 I Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global ...

OSLO, Norway I August 5, 2025 I Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced ...

DONGGUAN, China I August 5, 2025 I Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the ...

Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeutic Strategy' by ...

BOTHELL, WA, USA I August 05, 2025 I Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the presentation of favorable safety and tolerability data from a ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...

Continued progress positions Company to report topline data for Phase 1 clinical trial of SENTI-202 before year-end ...

Trial will evaluate DF-003, a first-in-class ALPK1 inhibitor that specifically targets the genetic root cause of ROSAH syndrome ...

CARLSBAD, CA, USA I August 04, 2025 I Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel ...

SOUTH SAN FRANCISCO, CA, USA I August 04, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human ...

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint – ...